Proxy Votes Now

Home › Funds › Franklin Templeton › Franklin Genomic Advancements ETF

Franklin Genomic Advancements ETF (HELX) proxy voting record 2025-2026

Fund family: Franklin Templeton · Filed by Franklin Templeton ETF Trust (CIK 1655589) · SEC series S000067393

Ticker: HELX (C000216720)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 562 with, 7 against, 0 abstentions (not counted as with management). Shareholder proposals: 6 FOR, 1 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Franklin Templeton as a whole

The same two figures as Franklin Templeton’s manager page (151,616 ballot items across 70 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsFranklin TempletonItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)89.7%52490.1%113,225
Backed environmental and social shareholder proposals at US companiesn/a18.3%1,123

Where this fund voted differently from most Franklin Templeton funds

Each ballot item this fund voted is set against the votes of the other Franklin Templeton funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Franklin Templeton funds on 2 items (0.9% of the 223 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Franklin Templeton fundsMgmtResult
Bristol-Myers Squibb Company2026-05-05Shareholder Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent DirectorForAGAINST — 7 of 8 Franklin Templeton fundsAgainstNot approved, 27.6% support
United Therapeutics Corporation2026-06-26Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.ForAGAINST — 3 of 4 Franklin Templeton fundsForPassed (calculated), 72.0% support

Download all 2 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 80.7% of this fund’s 569 such votes could be given a sector; the other 110 (19.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care37461.6%
Industrials4012.5%
Technology3100.0%
Consumer Staples1400.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections3390
Audit-related590
Say-on-Pay590
Compensation440
Corporate Governance405
Capital Structure300
Extraordinary Transactions40
Shareholder Rights and Defenses31
Other Social Issues21

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Guardant Health, Inc.June 17, 2026$5M50
Natera, Inc.June 11, 2026$4M80
Adaptive Biotechnologies CorporationJune 5, 2026$3M40
Krystal Biotech, Inc.May 15, 2026$3M50
Ligand Pharmaceuticals IncorporatedJune 5, 2026$2M110
United Therapeutics CorporationJune 26, 2026$2M150
BridgeBio Pharma, Inc.June 22, 2026$2M70
Medpace Holdings, Inc.May 15, 2026$2M111

Notable votes against management

MeetingCompanyProposalFundMgmt
May 15, 2026Medpace Holdings, Inc.Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
April 23, 2026IQVIA Holdings Inc.If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposalForAgainst
April 21, 2026Bio-Rad Laboratories, Inc.Stockholder proposal regarding dual class capital structure. Shareholder proposalForAgainst
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalForAgainst

Search this fund’s votes by company

580 ballot items at 63 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Franklin Genomic Advancements ETF (HELX) voted at 63 shareholder meetings of 60 companies, on 580 ballot items in all. Where management made a recommendation, the fund followed it on 98.8% of the items and voted against it 7 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals about as often as Franklin Templeton's funds as a whole (89.7% against 90.1%). It voted differently from most Franklin Templeton funds on 2 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Franklin Templeton’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.